How has MoonLake Immunotherapeutics - Ordinary Shares - Class A performed historically?

The MoonLake Immunotherapeutics - Ordinary Shares - Class A is currently trading down -3.20% on an intraday basis in the past week the index fell -9.10%. The index has been down -12.71% in the past quarter and fell -5.99% in the past year. You can view this in the overview section.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Annual Net Profit?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Annual Net Profit fell 230.31% in the last year to $118.94 M. Its sector's average net profit growth for the last fiscal year was -42.75%.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Price to Earning Ratio?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Price to Earning Ratio is -20.53, which is negative.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Quarterly Net profit?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Quarterly Net profit fell 513.2% YoY to $45.6 M. Its sector's average net profit growth YoY for the quarter was -40.08%.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Debt to Equity Ratio?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Return on Equity(ROE)?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Return on Equity(ROE) for the last financial year was -25.24%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Mutual Fund Holding?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Mutual Fund Holding decreased by 0.64% in the last quarter to 35.65.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Institutional Holding?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Institutional Holding increased by 0.17% in the last quarter to 100.16.

MoonLake Immunotherapeutics - Ordinary Shares - Class A XNAS: MLTX

MoonLake Immunotherapeutics - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

Name: MoonLake Immunotherapeutics - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: MoonLake Immunotherapeutics - Ordinary Shares - Class A
Rating: 0.99558325
Author: Trendlyne DVM scores

about

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibit...

38.47 -1.27 (-3.20%)

32.35% Fall from 52W High

273.6K XNAS Volume

XNAS 09 May, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for MoonLake Immunotherapeutics - Ordinary Shares - Class A is on 14 May 2025 for the purpose of MoonLake Immunotherapeutics First Quarter Earnings Results for 2025 See details

Not Eligible

Expensive Valuation

3.3 / 100

Technically Neutral

36.5 / 100

No estimates available

MoonLake Immunotherapeutic... Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

MoonLake Immunotherapeutics - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibit...

32.35% Fall from 52W High

SWOT Analysis

MoonLake Immunotherapeutic... Live Price Chart

MoonLake Immunotherapeutics - Ordinary Shares - Class A FAQ

How is MoonLake Immunotherapeutics - Ordinary Shares - Class A today?

MoonLake Immunotherapeutics - Ordinary Shares - Class A today is trading in the red, and is down by -3.20% at 38.47.

How has MoonLake Immunotherapeutics - Ordinary Shares - Class A performed historically?

MoonLake Immunotherapeutics - Ordinary Shares - Class A is currently trading down -3.20% on an intraday basis. In the past week the stock fell -9.10%. stock has been down -12.71% in the past quarter and fell -5.99% in the past year. You can view this in the overview section.